Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected ... Moving checkpoint inhibitors further up the treatment pathway into earlier adjuvant and neoadjuvant ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...